Bruker Corporation (Nasdaq: BRKR), a provider of high performance scientific instruments and high value analytical and diagnostic solutions, announced on Wednesday that it has successfully acquired Spectral Instruments Imaging LLC (SII), a provider of preclinical in-vivo optical imaging systems. This strategic move enhances the technology and product range of Bruker BioSpin Preclinical Imaging (PCI) division, strengthening its offerings for disease research.

Founded in 2009 in Tucson, Spectral Instruments Imaging is a pioneer in co-registered bioluminescence (BLI), fluorescence (FLI) and X-ray preclinical imaging. SII systems, including the flagship Lago X and high-efficiency AMI HTX, feature advanced optics, patented illumination, -90o C air-cooled high sensitivity cameras and absolute calibration for quantifiable imaging, ensuring flexibility and ease of use. The SII Aura software streamlines workflows for enhanced productivity.

Keith Copeland, CEO of SII, highlighted that the acquisition marks a significant milestone, anticipating that customers will benefit from a broader range of preclinical imaging modalities to understand biological disease processes comprehensively in vivo.

While financial details of the acquisition remain undisclosed, Spectral Instruments Imaging reported revenues exceeding USD10m and profitability in 2023. Bruker's acquisition aligns with its commitment to empowering scientists through high-performance instruments and analytical solutions, fostering innovation and success in various life science disciplines, including preclinical imaging, clinical phenomics research, proteomics and multiomics, among others.